胆汁酸类似物拦截肝纤维化
C Daniel De Magalhaes Filho1, Michael Downes1, Ron Evans1
1Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
Cell
|August 13, 2016
概括
Ocaliva是一种合成胆汁酸类比剂,有效治疗无反应乌尔索酸 (UDCA) 的患者的初级胆汁炎. 这种FXR激动剂为自身免疫性肝病的治疗提供了替代方案.
科学领域:
- 肝病学
- 药理学
- 免疫学
背景情况:
- 原发性胆道炎 (PBC) 是一种慢性自身免疫性肝病.
- 乌尔索多西可酸 (UDCA) 是常规的治疗方法,但有些患者表现出不充分的反应或不耐受.
- 核胆酸受体Farnesoid X受体 (FXR) 在胆酸平衡中起作用.
研究的目的:
- 评估Ocaliva (奥贝蒂科尔酸) 在治疗初级胆道胆炎的疗效.
- 评估Ocaliva作为对UDCA不耐受或不反应的PBC患者的治疗选择.
主要方法:
- Ocaliva是一种针对FXR的合成胆酸模拟剂.
- 给患有初级胆管炎的患者使用Ocaliva.
主要成果:
- 在治疗初级胆道炎方面,Ocaliva 已显示出有效性.
- 对于对UDCA治疗不耐药的PBC患者,Ocaliva提供了一个治疗选择.
结论:
- 奥卡利瓦是一种有效的治疗原发性胆道炎.
- 对于传统治疗失败的自身免疫性肝病患者,Ocaliva提供了一个有价值的治疗替代方案.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
313
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
313
Ultrasound II: Endoscopic Ultrasound and FibroScan
998
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
998
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Hepatic Drug Excretion: Enterohepatic Cycling
3.2K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
325
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
325


